Brown, Lisle/Cummings, Inc. Arbutus Biopharma Corp Transaction History
Brown, Lisle/Cummings, Inc.
- $294 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding ABUS
# of Institutions
130Shares Held
82.2MCall Options Held
4.82MPut Options Held
546K-
Whitefort Capital Management, LP New York, NY12.9MShares$40.1 Million24.48% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$32.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY8.83MShares$27.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY7.84MShares$24.5 Million10.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$18.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $468M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...